Pharmacoeconomic efficiency of tezepelumab for the treatment of patients with severe asthma in the Russian Federation
https://doi.org/10.18093/0869-0189-2025-35-3-380-389
Abstract
Bronchial asthma is one of the most common chronic non-infectious inflammatory diseases of the respiratory tract. Asthma is characterized by significant phenotypic and endotypic heterogeneity, which complicates the selection of therapy in patients.
The aim was to assess the clinical and economic feasibility of tezepelumab compared to the standard therapy in patients with severe asthma (SA) in the Russian Federation.
Methods. A clinical and economic analysis of the use of tezepelumab in combination with the standard therapy was conducted in comparison with the standard therapy for SA only. The study period was 5 years. The study was performed using cost-effectiveness analysis. The costs were calculated with a mathematical model adapted to the health care conditions in the Russian Federation. The study considered both direct costs (for drug therapy, hospitalization, outpatient care) and indirect costs (disability payments and losses of gross domestic product – GDP).
Results. Over a 5-year modeling horizon, the use of tezepelumab added 0.413 years of life and 0.352 years of quality life compared to the standard therapy, while reducing total costs by RUB 2,069,322 due to a reduction in GDP losses due to mortality and temporary disability. As a result of using tezepelumab, the number of days of disability was reduced almost 2-fold compared to the standard therapy (115 days vs 177 days). Costs in the 1st year of modeling were calculated separately, showing a decrease in total costs by RUB 245,393 when using tezepelumab. Thus, therapy of patients with SA with tezepelumab is clinically justified because it leads to an increase in the working life expectancy of patients with asthma. It is also economically feasible, since it leads to a reduction in indirect costs and GDP losses for the state.
Conclusion. The use of tezepelumab in the patients with SA is pharmacoeconomically effective compared to the standard therapy in the Russian Federation.
Keywords
severe bronchial asthma,
tezepelumab,
biologics,
effectiveness analysis,
cost analysis,
pharmacoeconomic modeling
Supporting agencies: The study was prepared with the financial support of AstraZeneca Pharmaceuticals LLC
About the Authors
S. V. Nedogoda
Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Sergey V. Nedogoda - Doctor of Medicine, Professor, Head of the Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education.
Pavshikh Bortsov pl. 1, Volgograd, 400066; tel.: (8442) 97-42-51
Competing Interests:
The authors have not declared any conflict of interest
S. N. Avdeev
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Sergey N. Avdeev - Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Director of the National Medical Research Center for Pulmonology; Head of the Department of Pulmonology, N.V. Sklifosovsky Institute of Clinical Medicine, Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow SMU of the Ministry of Health of the Russian Federation (Sechenov University); Head of Clinical Department, Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation; Chief Pulmonologist of the Ministry of Health of the RF.
Ul. Trubetskaya 8, build. 2, Moscow, 119991; Orekhovyy bul’var 28, Moscow, 115682; tel.: (495) 708-35-76
Competing Interests:
The authors have not declared any conflict of interest
A. S. Salasyuk
Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Alla S. Salasyuk - Doctor of Medicine, Professor, Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education.
Pavshikh Bortsov pl. 1, Volgograd, 400066; tel.: (8442) 97-42-53
Competing Interests:
The authors have not declared any conflict of interest
I. N. Barykina
Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Irina N. Barykina - Сandidate of Medicine, Associate Professor, Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education.
Pavshikh Bortsov pl. 1, Volgograd, 400066; tel.: (8442) 97-42-53
Competing Interests:
The authors have not declared any conflict of interest
V. O. Lutova
Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Victoria O. Lutova - Сandidate of Medicine, Associate Professor, Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education.
Pavshikh Bortsov pl. 1, Volgograd, 400066; tel.: (8442) 97-42-53
Competing Interests:
The authors have not declared any conflict of interest
E. A. Popova
Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Ekaterina A. Popova - Сandidate of Medicine, Associate Professor, Department of Internal Medicine, Institute of Continuous Medical and Pharmaceutical Education.
Pavshikh Bortsov pl. 1, Volgograd, 400066; tel.: (8442) 97-42-53
Competing Interests:
The authors have not declared any conflict of interest
References
1. Ministry of Health of the Russian Federation. [Clinical guidelines: Bronchial asthma]. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/359_3 [Accessed: December 10.12.2024] (in Russian).
2. Nenasheva N.M. [Tezepelumab – a new genetically engineered biological drug for the treatment of severe bronchial asthma]. Prakticheskaya pul'monologiya. 2023; (2): 3–13. DOI: 10.24412/2409-6636-2023-12872 (in Russian).
3. Global Initiative for Asthma. Summary Guide for Asthma Management and Prevention: for Adults, Adolescents and Children 6–11 years. Updated 2024. Available at: https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf [Accessed: December 27, 2024].
4. Omel'yanovskiy V.V., ed. [Social-economic burden of asthma and COPD in the Russian Federation]. Moscow: Kachestvo zhizni; 2010 (in Russian).
5. Zyryanov S.K., Dyakov I.N., Karpov O.I. [Modeling of the impact of biological drugs in the economic burden of severe asthma]. Kachestvennaya klinicheskaya praktika. 2019; (3): 4–12. DOI: 10.24411/2588-0519-2019-10078 (in Russian).
6. Krysanov I.S., Krysanova V.S., Ermakova V.Yu. [A social-economic burden of rhinosinusitis with nasal polyps with comorbid asthma and influence of dupilumab]. Kachestvennaya klinicheskaya praktika. 2021; (3): 16–30. DOI: 10.37489/2588-0519-2021-3-16-30 (in Russian).
7. Krysanov I.S., Krysanova V.S., Karpov O.I., Ermakova V.Yu. [Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis]. Kachestvennaya klinicheskaya praktika. 2020; (3): 15–26. DOI: 10.37489/2588-0519-2020-3-15-26 (in Russian).
8. Belevskiy A.S., Nenasheva N.M., Kravchenko N.Yu. et al. [Data from the Russian Severe Asthma Registry (RSAR). Terapevticheskiy arkhiv. 2022; 94 (7): 865–871. DOI: 10.26442/00403660.2022.07.201713 (in Russian).
9. Avdeev S.N., Nenasheva N.M., Zhudenkov K.V. et al. [The prevalence, incidence, phenotypes and other characteristics of severe bronchial asthma in the Russian Federation]. Pul'monologiya. 2018; 28 (3): 341–358. DOI: 10.18093/0869-0189-2018-28-3-341-358 (in Russian).
10. Nenasheva N.M. [Biological therapy of bronchial asthma: present and future]. Consilium Medicum. 2016; 18 (11): 30–38. Available at: https://consilium.orscience.ru/2075-1753/article/view/94556 [in Russian].
11. Akenroye A., McCormack M., Keet C. Severe asthma in the US population and eligibility for mAb therapy. J. Allergy Clin. Immunol. 2020; 145 (4): 1295–1297.e1296. DOI: 10.1016/j.jaci.2019.12.009.
12. Denton E., Price D.B., Tran T.N. et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J. Allergy Clin. Immunol. Pract. 2021; 9 (7): 2680–2688.e7. DOI: 10.1016/j.jaip.2021.02.059.
13. Albers F.C., Müllerová H., Gunsoy N.B. et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J. Asthma. 2018; 55 (2): 152–160. DOI: 10.1080/02770903.2017.1322611.
14. Menzies-Gow A., Wechsler M.E., Brightling C.E. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir. Res. 2020; 21 (1): 268. DOI: 10.1186/s12931-020-01505-x.
15. Corren J., Parnes J.R., Wang L. et al. Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 2017; 377 (10): 936–946. DOI: 10.1056/NEJMoa1704064.
16. Menzies-Gow A., Corren J., Bourdin A. et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N. Engl. J. Med. 2021; 384 (19): 1800–1809. DOI: 10.1056/NEJMoa2034975.
17. Wechsler M.E., Menzies-Gow A., Brightling C.E. et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir. Med. 2022; 10 (7): 650–660. DOI: 10.1016/S2213-2600(21)00537-3.
18. National Institute for Health and Care Excellence (NICE). Benralizumab for treating severe eosinophilic asthma. Technology appraisal guidance [TA565]. 2019. Available at: https://www.nice.org.uk/guidance/ta565/resources/benralizumab-for-treating-severe-eosinophilic-asthma-pdf-82607084018629 [Accessed: January 26, 2024].
19. National Institute for Health and Care Excellence (NICE). Tezepelumab for treating severe asthma. Technology appraisal guidance. TA880. 2023. Available at: https://www.nice.org.uk/guidance/ta880/resources/tezepelumab-for-treating-severe-asthma-pdf-82613726899909 [Accessed: January 26, 2024].
20. Demoscope Weekly. [Russia life tables 2014 the human mortality database. Russia. Life tables by year of death (period), 1959–2014]. Available at: https://www.demoscope.ru/weekly/search.php (in Russian).
21. Ministry of Health of the Russian Federation. [Minutes of the meeting of the commission of the Ministry of Health of the Russian Federation on the formation of lists of drugs for medical use and the minimum range of drugs necessary for the provision of medical care]. Available at: https://minzdrav.gov.ru/ministry/61/10/stranitsa-858/stranitsa-7810 [Accessed: September 28, 2024] (in Russian).
22. The State Register of Medicines. [Instructions for medical use: Tezspire (tezepelumab)]. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8aef56a3-5fee-4b98-be6b-562dfb02bbb3 [Accessed: August 28, 2024] (in Russian).
23. Ministry of Health of the Russian Federation. [Methodological recommendations on methods of paying for medical care at the expense of compulsory health insurance (joint letter dated January 26, 2023 of the Ministry of Health of the Russian Federation No.31-2/I/2-1075 and the Federal Compulsory Medical Insurance Fund No.00-10-26-2-06/749) and decoding of groups for medical care provided in an inpatient setting, and decoding of groups for medical care provided in a day hospital]. Available at: https://www.ffoms.gov.ru/upload/iblock/349/3496b00f7d7f1d570beedf91cbc9e91b.pdf (in Russian).
24. Russian Federation. [Decree of the Government of the dated December 28, 2023 No. 2353 “On the Program of State Guarantees for the provision of free medical care to citizens for 2024 and for the planning period of 2025 and 2026. Available at: http://publication.pravo.gov.ru/document/0001202312290105 [Accessed: May 21, 2024] (in Russian).
25. Willson J., Bateman E.D., Pavord I. et al. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists. Appl. Health Econ. Health Policy. 2014; 12 (4): 447–459. DOI: 10.1007/s40258-014-0107-8.
26. [Order of the Ministry of Economic Development of Russia No.192, Ministry of Health and Social Development of Russia No.323n, Ministry of Finance of Russia No.45n, Rosstat No.113 of 04/10/2012. On approval of the Methodology for calculating economic losses from mortality, morbidity and disability of the population. Available at: https://www.consultant.ru/document/cons_doc_LAW_129302/ (in Russian).
27. Federal State Statistics Service. [The employment rate of the population by age group. In: Labor force, employment and unemployment in Russia (based on the results of sample surveys of the labor force) 2024. Statistical collection]. Moscow: Rosstat; 2024: 38. Available at: https://rosstat.gov.ru/storage/mediabank/Rab_sila_2024.pdf [Accessed: June 21, 2024] (in Russian).
28. Federal State Statistics Service. [Labor market, employment and wages]. Available at: https://rosstat.gov.ru/labor_market_employment_salaries [Accessed: May 21, 2024] (in Russian).
29. Federal State Statistics Service. [GDP years by income (since 1995)]. Available at: https://rosstat.gov.ru/search?q=ВВП+годы+по+доходам+%28с+1995+г.%29 [Accessed: May 21, 2024] (in Russian).
30. Nedogoda S.V., Salasyuk A.S., Avdeev S.N. et al. [Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma]. Farmakoekonomika. Sovremennaya farmakoekonomika, i farmakoepidemiologiya. 2023; 16 (4): 527–536. DOI: 10.17749/2070-4909/farmakoekonomika.2023.223 (in Russian).
31. Habash M., Guiang H., Mayers I. et al. Cost-effectiveness of tezepelumab in Canada for severe asthma. J. Med. Econ. 2023; 26 (1): 902–914. DOI: 10.1080/13696998.2023.2234235.
32. CDAAMC. Tezepelumab. 2022. Available at: https://www.cadth.ca/tezepelumab
Supplementary files
Review
For citations:
Nedogoda S.V., Avdeev S.N., Salasyuk A.S., Barykina I.N., Lutova V.O., Popova E.A. Pharmacoeconomic efficiency of tezepelumab for the treatment of patients with severe asthma in the Russian Federation. PULMONOLOGIYA. 2025;35(3):380-389. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-3-380-389
Views:
145
Email this article 